Agendia BV And CBLpath Announce Agreement To Assist Physicians In Diagnostic Assessment Of Breast Cancer

IRVINE, Calif. & AMSTERDAM & RYE BROOK, N.Y.--(BUSINESS WIRE)--Agendia, a leading molecular diagnostics company, and CBLPath, Inc., a leading pathology services provider, today announced they have agreed to collaborate in providing molecular diagnostics testing to breast cancer patients.

“We expect this collaboration to have a significant clinical impact,” said Neil Barth, M.D., Agendia’s Chief Medical Officer. “A large part of CBLPath’s focus is on breast cancer. Agendia’s MammaPrint test is a sophisticated assay for breast cancer recurrence risk. Through our BluePrint assay, we also provide a widely available test for molecular subtyping of breast cancer. By working more closely together, Agendia and CBLPath will move the treatment of breast cancer toward better outcomes and fewer unnecessary side-effects.”

Help employers find you! Check out all the jobs and post your resume.